title: Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
abstract: Natalizumab is currently the most successful clinical treatment for multiple sclerosis. The use of this drug is associated with the reduction in the number of relapses and a slowing in disease progression, as well as an improvement in signs and symptoms displayed by the patients. To evaluate the effect of natalizumab on melatonin and its relationship with peripheral oxidative damage, we studied the serum melatonin levels in 18 patients with relapsing-remitting multiple sclerosis. Natalizumab caused significant increases in serum melatonin concentrations. This change was associated with a rise in increase of antioxidants and a reduction in oxidative stress biomarkers. In conclusion, these data may explain, at least in part, some of the beneficial effects exhibited by disease antibody such as its antioxidant capacity.
authors.affiliation: Department of Neurology, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Bahamonde
authors.affiliation: Department of Neurology, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Conde
authors.affiliation: Department of Neurology, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Agüera
authors.affiliation: Department of Sociosanitary, Radiology and Physical Medicine, Psychiatry Section, Faculty of Medicine, University of Cordoba, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Lillo
authors.affiliation: Department of Morphological Sciences, Histology Section, Faculty of Medicine/ IMIBIC/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Evelio
authors.initials: E
authors.lastname: Luque
authors.affiliation: Department of Clinical Analysis, IMIBIC/Regional Hospital of Pedroches Valley/University of Cordoba, Spain.
authors.forename: Félix
authors.initials: F
authors.lastname: Gascón
authors.affiliation: Department of Biochemistry and Molecular Biology, Faculty of Medicine/IMIBIC/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Feijóo
authors.affiliation: Department of Clinical Analysis, IMIBIC/Regional Hospital of Pedroches Valley/University of Cordoba, Spain.
authors.forename: Antonio H
authors.initials: AH
authors.lastname: Cruz
authors.affiliation: Department of Neurology, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Sánchez-López
authors.affiliation: Department of Biochemistry and Molecular Biology, Faculty of Medicine/IMIBIC/Reina Sofia University Hospital/University of Cordoba, Spain. Electronic address: fm2tufii@uco.es.
authors.forename: Isaac
authors.initials: I
authors.lastname: Túnez
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000097:blood*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism*; D000069442:Natalizumab; D018384:Oxidative Stress / Q000187:drug effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D000069442:Natalizumab; D008550:Melatonin
keywords: Melatonin; Natalizumab; Oxidative stress; Relapsing-remitting multiple sclerosis; Tysabri(®)